NorDiag has postponed finalization of its financial statements for 2011 and accordingly the general annual meeting. The Company needs to do new impairment tests of intangible assets following the Company's financial situation. This may change the company's previous reported results for the year. Finalization is currently scheduled to the end of April.

For further information, please contact:
CEO Mårten Wigstøl, Phone: +47 911 65775
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNAfrom difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 29.15 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.